Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MarketBeat

Intel Could Be the Biggest Winner of TSMC’s AI Bottleneck

The AI industry's demand for chips is creating a supply bottleneck, positioning Intel's growing foundry business for significant long-term growth.

MarketBeat

Biohaven Insiders Bet $33 Million on a Turnaround

Biohaven's leadership made a massive multi-million dollar investment in their own stock, signaling deep confidence in the company's turnaround plan.

MarketBeat

Lowe’s Stock Price Signals a Buying Opportunity After Q3 Release

Lowe's is on track for a robust rebound and could set new highs in 2026, driven by its expanding pro business, cash flow, and capital returns.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought

NVIDIA is positioned for another potentially triple-digit stock price advance, driven by Q3 outperformance, a guidance increase, and an outlook for 2026.

MarketBeat

Why Target Stock May Keep Falling Despite a 5% Dividend Yield

Target is setting up for a rebound, but is unlikely to begin until 2026. Until then, there is a risk the downtrend will continue.

MarketBeat

Is Tesla Setting Up for a Year-End Rebound—or a Collapse?

Tesla’s $400 support has been holding strong, keeping its uptrend alive. But with bulls and bears split, the next few weeks could decide the year’s finish.

MarketBeat

Applied Materials: Up 40% in 2025 With Room to Run Long-Term

Applied Materials' latest earnings showed a significant drop in sales and EPS. However, shares are up big in 2025, with room to keep moving higher long-term.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

onsemi Places a $6 Billion Bet on Its Own Stock

onsemi's new multi-billion-dollar share repurchase program signals strong management confidence in its future growth and commitment to shareholder value.

MarketBeat

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

MarketBeat

End the Year Strong With These 3 Comeback Champions

Delta Air Lines, Diamondback Energy, and HEICO could all benefit from internal and external drivers of momentum heading into the end of the year.

MarketBeat

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

Novo Nordisk's new pricing for its GLP-1 drugs is a strategic pivot to capture a mass market, pressure rivals, and secure long-term market dominance.

MarketBeat

Institutions Love These 3 Companies, Should You As Well?

Retail investors seeking companies vetted by professionals might look to these three companies, all of which are heavily owned by institutional investors.

MarketBeat

3 Data Center Stocks Are Soaring—Analysts Think 1 Could Go Higher

As many data center stocks soar, see where Wall Street analysts are showing trepidation and where they are favoring the potential for upside.

MarketBeat

Why GRAIL Stock Could Be Biotech’s Next Big Breakout

Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Why Ford's Deal With Amazon Is Bigger Than You Think

Ford's Amazon partnership for used cars marks a monumental shift, creating a capital-efficient retail model that leverages its vast dealer network.

MarketBeat

Buyer Beware: Carvana Is Driving an Auto Lending Crisis

Carvana has posted enormous gains over the past two years, but its questionable lending practices and underlying financials warrant some concern.

MarketBeat

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

MarketBeat

Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum

Medtronic is on track to advance in 2026 and could rise by 20% to 30% before year-end. Analysts and institutions are accumulating in 2025.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Why Intuitive Machines Is Taking Off While Broader Market Sinks

Intuitive Machines stock is surging despite a weak market. A new acquisition, bullish analyst sentiment, and insider buying point to long-term growth potential

MarketBeat

What’s on the Thanksgiving Table? A Stock Pick for Every Course

Seaboard, Campbell’s, General Mills, McCormick, and Constellation Brands match every Thanksgiving course—with stocks that could rise this season.

MarketBeat

Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain

Home Depot's Q4 2025 price pullback is a great time to load up on this buy-and-hold stock. The stage is set for a 2026 rebound.

MarketBeat

Qualcomm’s Bulls Are Running Out of Room to Be Wrong

Qualcomm’s 20% drop means the bulls have given up all their post-earnings gains, and are once again on the backfoot defending a key support line.

MarketBeat

Amazon Just Did This—and It Didn't End Well Last Time

Amazon’s RSI crash mirrors last year's setup that preceded a 35% drop. But strong fundamentals would make any dip a major buy this time around.

MarketBeat

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

MarketBeat

Stellantis Makes a High-Stakes Bet on Jeep

A product-led revival of the iconic Jeep brand is driving Stellantis's North American recovery, signaling an opportunity for investors.

1 … 30 31 32 33

People

Andrew Dudum

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.